1. Search Result
Search Result
Results for "

DNA gyrase

" in MCE Product Catalog:

62

Inhibitors & Agonists

10

Natural
Products

13

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-147945
    DNA gyrase B-IN-1

    DNA/RNA Synthesis Bacterial Infection
    DNA gyrase B-IN-1 (compound 13) is a potent DNA gyrase B inhibitor. DNA gyrase B-IN-1 shows inhibition of P. aeruginosa/i> DNA gyrase B, with an IC50 of 2.2 μM. DNA gyrase B-IN-1 has good binding affinity and stability.
  • HY-147818
    DNA Gyrase-IN-2

    Bacterial DNA/RNA Synthesis Infection
    DNA Gyrase-IN-2 (Compound 22a) is a bacterial DNA gyrase B inhibitor with IC50s of 3.29-10.49 and 4.41-5.61 µM for E. coli DNA gyrase and M. tuberculosis DNA gyrase. Anti-tubercular and antibacterial activity.
  • HY-147819
    DNA Gyrase-IN-3

    Bacterial DNA/RNA Synthesis Infection
    DNA Gyrase-IN-3 (Compound 28) is a bacterial DNA gyrase B inhibitor with IC50s of 5.41-15.64 µM for E. coli DNA gyrase. Anti-tubercular and antibacterial activity.
  • HY-147948
    DNA Gyrase-IN-4

    DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-4 (compound 8p) is a potent DNA gyrase inhibitor, with an IC50 of 0.13 μM. DNA Gyrase-IN-4 shows excellent antibacterial activity against Staphylococcus aureus, Listeria monocytogenes, Salmonella and Escherichia coli, with MIC values of 0.05, 0.05, 0.05, and 8 μg/mL, respectively.
  • HY-147000
    DNA Gyrase-IN-1

    Bacterial DNA/RNA Synthesis Infection
    DNA Gyrase-IN-1 (compound 42) is a potent and selective DNA gyrase inhibitor with an IC50 value of 2.6 µM. DNA Gyrase-IN-1 has high inhibitory activity against Mycobacterium tuberculosis (Mtb) with MIC of 0.49 µM. DNA Gyrase-IN-1 can be used for researching tuberculosis.
  • HY-147988
    DNA Gyrase-IN-5

    DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-5 (Compound 8I-w) is a potent DNA gyrase inhibitor with an IC50 of 0.10 μM. DNA Gyrase-IN-5 shows antibacterial activities against wild type and drug-resistant strains.
  • HY-147777
    14α-Demethylase/DNA Gyrase-IN-2

    Bacterial DNA/RNA Synthesis Infection
    14α-Demethylase/DNA Gyrase-IN-2 (Compound 6a) is a potent inhibitor of 14α-Demethylase/DNA Gyrase. 14α-Demethylase/DNA Gyrase-IN-2 has antimicrobial activities.
  • HY-147778
    14α-Demethylase/DNA Gyrase-IN-1

    Bacterial DNA/RNA Synthesis Infection
    14α-Demethylase/DNA Gyrase-IN-1 (Compound 7c) is a potent inhibitor of 14α-Demethylase/DNA Gyrase. 14α-Demethylase/DNA Gyrase-IN-1 has antimicrobial activities.
  • HY-143483
    NBTIs-IN-5

    Bacterial Infection
    NBTIs-IN-5 (Compound 5r) is a NBTI (Novel Bacterial Topoisomerase Inhibitor) DNA gyrase inhibitor with an IC50 of 1.5 μM against Mycobacterium abscessus (Mabs) DNA gyrase. NBTIs-IN-5 inhibits Mabs bamboo bacterial growth with an MIC90 of 0.4 μM.
  • HY-143482
    MMV688844

    Bacterial DNA/RNA Synthesis Infection
    MMV688844 is a potent Mycobacterium abscessus (Mabs) DNA Gyrase inhibitor with an IC50 value of 2 μM. MMV688844 has bactericidal properties against Mabs bamboo with a MIC50 of 12 μM. MMV688844 can be used for researching anti-bacteria.
  • HY-N2150
    Psammaplin A

    HDAC DNA Methyltransferase DNA/RNA Synthesis Bacterial Cancer Infection
    Psammaplin A, a marine metabolite, is a potent inhibitor of HDAC and DNA methyltransferases. Psammaplin A ia a highly potent and selective DAC1 inhibitor with an IC50 of 0.9 nM. Psammaplin A possess the antimicrobial effect on the Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Antitumor Activity.
  • HY-143484
    844-TFM

    Bacterial Infection
    844-TFM is a NBTI (novel bacterial topoisomerase inhibitor) DNA gyrase inhibitor, with an IC50 of 1.5 μM. 844-TFM exhibits bactericidal properties against M. abscessus.
  • HY-115990
    Topoisomerase IV inhibitor 1

    Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively.
  • HY-115991
    Topoisomerase IV inhibitor 2

    Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 5d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.35 μM and 0.55 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively.
  • HY-B0330A
    Levofloxacin hydrate

    Levofloxacin hemihydrate

    Bacterial Antibiotic Topoisomerase DNA/RNA Synthesis Infection
    Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrate inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrate can be used for chronic periodontitis, airway inflammation and BK Viremia research.
  • HY-B0330B
    Levofloxacin hydrochloride

    (-)-Ofloxacin hydrochloride

    Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Infection
    Levofloxacin ((-)-Ofloxacin) hydrochloride is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrochloride can be used for chronic periodontitis, airway inflammation and BK Viremia research.
  • HY-B0330
    Levofloxacin

    (-)-Ofloxacin

    Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Orthopoxvirus Infection Cancer
    Levofloxacin ((-)-Ofloxacin) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin inhibits the DNA gyrase and topoisomerase IV. Levofloxacin can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin shows anti-orthopoxvirus activity.
  • HY-B0398
    Nalidixic acid

    Bacterial Antibiotic Topoisomerase Infection
    Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria.
  • HY-B0398A
    Nalidixic acid sodium salt

    Bacterial Antibiotic Topoisomerase Infection
    Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria.
  • HY-B0268A
    Enoxacin hydrate

    Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Infection Cancer
    Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-B0268
    Enoxacin

    AT 2266; CI 919

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-146403
    Antibacterial agent 98

    Bacterial Infection
    Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus).
  • HY-B0147A
    Pefloxacin mesylate

    Pefloxacinium mesylate

    Bacterial Antibiotic Infection
    Pefloxacin mesylate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse) Target: DNA gyrase Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections.
  • HY-B0147
    Pefloxacin

    Pefloxacinium

    Bacterial Antibiotic Infection
    Pefloxacin is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse) Target: DNA gyrase Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections.
  • HY-A0170
    Trovafloxacin

    Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1.
  • HY-103399
    Trovafloxacin mesylate

    Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1.
  • HY-B0147B
    Pefloxacin mesylate dihydrate

    Pefloxacinium mesylate dihydrate

    Bacterial Antibiotic Infection
    Pefloxacin mesylate dehydrate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse) Target: DNA gyrase Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections.
  • HY-N7066
    Difloxacin hydrochloride

    Bacterial Antibiotic Infection
    Difloxacin hydrochloride is a broad-spectrum antibacterial drug. Difloxacin hydrochloride inhibits bacterial DNA gyrase and exhibits a concentration-dependant bactericidal effect by interference with the activity of DNA gyrase and topoisomerase IV.
  • HY-135389
    Desmethyl Levofloxacin

    Drug Metabolite Infection
    Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-B0330S1
    (S)-Ofloxacin-d3

    Bacterial Antibiotic Infection
    (S)-Ofloxacin-d3 is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-B0330S
    Levofloxacin-d8

    (-)-Ofloxacin-d8

    Bacterial Antibiotic Infection
    Levofloxacin-d8 ((-)-Ofloxacin-d8) is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-18714
    BRD7116

    Bacterial Others
    BRD7116 competitively binds to bacterial DNA gyrase, exhibits an EC50 of 200 nM for LSCe cells, with cell-non-autonomous anti-leukemia activity.
  • HY-147729
    UIAA-II-232

    DNA/RNA Synthesis Infection
    UIAA-II-232 (compound 19b) is a potent DNA gyrase catalytic inhibitor with an IC50 value of 3.5 µM.
  • HY-135389S
    Desmethyl Levofloxacin-d8 hydrochloride

    Drug Metabolite Antibiotic Infection
    Desmethyl Levofloxacin-d8 hydrochloride is the deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-135389S1
    Desmethyl Levofloxacin-d8

    Drug Metabolite Antibiotic Infection
    Desmethyl Levofloxacin-d8 is deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
  • HY-B0132A
    Norfloxacin hydrochloride

    MK-0366 hydrochloride

    Bacterial Antibiotic Infection
    Norfloxacin hydrochloride (MK-0366 hydrochloride) is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria, which functions by inhibiting DNA gyrase.
  • HY-N2033
    Chebulinic acid

    DNA/RNA Synthesis TGF-beta/Smad Proton Pump Infection
    Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
  • HY-B0132
    Norfloxacin

    MK-0366

    Bacterial Endogenous Metabolite Antibiotic Infection
    Norfloxacin (MK-0366) is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria, which functions by inhibiting DNA gyrase.
  • HY-B0125
    Ofloxacin

    Hoe-280

    Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus Infection
    Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).
  • HY-132923
    NBTIs-IN-4

    Bacterial Infection
    NBTIs-IN-4 demonstrates potent antibacterial activity against diverse Gram-positive pathogens, inhibition of both DNA gyrase and topoisomerase IV, a low frequency of resistance.
  • HY-101472
    Closthioamide

    Bacterial Infection
    Closthioamide is a potent inhibitor of bacterial DNA gyrase and highly active against Ec, MRSA, VRE and Mv), with MICs of 9.00 μM, 0.58 μM, 0.58 μM and 72.03 μM respectively.
  • HY-N7452
    Coumermycin A1

    JAK Bacterial Metabolic Disease
    Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.
  • HY-B0125S1
    Ofloxacin-d8

    Bacterial Antibiotic Infection
    Ofloxacin-d8 (Hoe-280-d8) is the deuterium labeled Ofloxacin. Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase.
  • HY-B0398S
    Nalidixic Acid-d5

    Bacterial Antibiotic Topoisomerase Infection
    Nalidixic Acid-d5 is the deuterium labeled Nalidixic acid. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria.
  • HY-12888
    AZD5099

    Topoisomerase Bacterial Infection
    AZD5099, an antibacterial agent, is a potent and selective bacterial topoisomerase II inhibitor. AZD5099 potently inhibits the infections caused by Gram-positive and fastidious Gram-negative bacteria.
  • HY-B0132S1
    Norfloxacin-d8

    MK-0366-d8

    Bacterial Endogenous Metabolite Antibiotic Infection
    Norfloxacin-d8 (MK-0366-d8) is the deuterium labeled Norfloxacin. Norfloxacin (MK-0366) is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria, which functions by inhibiting DNA gyrase.
  • HY-17647
    Zoliflodacin

    ETX0914; AZD0914

    DNA/RNA Synthesis Bacterial Infection
    Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC90 of 0.25 μg/mL.
  • HY-B0425A
    Novobiocin sodium

    Albamycin sodium; Cathomycin sodium

    Bacterial Antibiotic Orthopoxvirus Apoptosis DNA/RNA Synthesis HSP Infection Cancer
    Novobiocin (Albamycin) sodium is a potent and orally active antibiotic. Novobiocin sodium also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin sodium has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin sodium shows anti-orthopoxvirus activity.
  • HY-109785A
    (R)-Gyramide A hydrochloride

    Infection
    (R)-Gyramide A hydrochloride is a bacterial DNA gyrase inhibitor that disrupts supercoiling activity with an IC50 value of 3.3 µM. (R)-Gyramide A hydrochloride demonstrates antibacterial activity against E. coli, P. aeruginosa, and S. enterica (MICs of 10-80 µM). (R)-Gyramide A hydrochloride does not affect the closely related enzyme topoisomerase IV.
  • HY-W011117S
    Danofloxacin-d3

    Bacterial DNA/RNA Synthesis Infection
    Danofloxacin-d3 is deuterium labeled Danofloxacin. Danofloxacin is a third generation fluoroquinolone and orally active antimicrobial agent. Danofloxacin shows a broad spectrum of activity against most Gram-negative and Gram-positive bacteria, mycoplasma and chlamydia species, and plays an antimicrobial role by inhibition of bacterial DNA-gyrase.
  • HY-W011117
    Danofloxacin

    Bacterial DNA/RNA Synthesis Antibiotic Infection
    Danofloxacin is a third generation fluoroquinolone and orally active antimicrobial agent. Danofloxacin shows a broad spectrum of activity against most Gram-negative and Gram-positive bacteria, mycoplasma and chlamydia species, and plays an antimicrobial role by inhibition of bacterial DNA-gyrase. Danofloxacinh has the potential for respiratory diseases in cattle, swine, and chickens treatment.
  • HY-B0536A
    Clinafloxacin hydrochloride

    AM 1091 hydrochloride; CI 960 hydrochloride; PD127391 hydrochloride

    Bacterial Antibiotic Infection
    Clinafloxacin hydrochloride (AM 1091 hydrochloride) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro. Clinafloxacin hydrochloride is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively.
  • HY-B0536
    Clinafloxacin

    AM-1091; CI-960; PD 127391

    Bacterial Antibiotic Infection
    Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro. Clinafloxacin is against DNA gyrase and topoisomerase IV of S. aureus with IC50 values of 0.92 µg/ml and 1.62 µg/ml, respectively.
  • HY-10581A
    Gatifloxacin hydrochloride

    AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
  • HY-10581B
    Gatifloxacin mesylate

    AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
  • HY-10581
    Gatifloxacin

    AM-1155; BMS-206584; PD135432

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml). Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
  • HY-16745
    Lascufloxacin

    KRP-AM1977X

    Bacterial Infection
    Lascufloxacin (KRP-AM1977X) is a potent and orally active fluoroquinolone antibacterial agent. Lascufloxacin potently inhibits infections caused by various pathogens, including quinolone-resistant strains. Lascufloxacin has the potential for various infectious diseases treatment, including lower respiratory tract infections.
  • HY-10581C
    Gatifloxacin sesquihydrate

    AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate

    Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
  • HY-B0268S1
    Enoxacin-d8 hydrochloride

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin-d8 (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-10581AS
    Gatifloxacin-d3 hydrochloride

    AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
  • HY-B0268S
    Enoxacin-d8

    Bacterial DNA/RNA Synthesis MicroRNA Antibiotic Cancer Infection
    Enoxacin-d8 (AT 2266-d8) is the deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.
  • HY-103399S
    Trovafloxacin-d4 mesylate

    Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin-d4 mesylate is the deuterium labeled Trovafloxacin mesylate. Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1.